Kallyope Announces $66M Series B Financing at $2.00 per share to Advance Programs Targeting the Gut-Brain Axis Portfolio News / By admin February 22, 2018
Aragon’s Drug ARN509 (Now Johnson&Johnson’s Erleada) Gets Quick Push Over the Finish Line by the FDA, with First-Ever Non-Metastatic Prostate Cancer Nod Portfolio News / By admin February 15, 2018
Aragon’s Drug Apalutamide Gets FDA Approval for Nonmetastatic Castration-Resistant Prostate Cancer Portfolio News / By admin February 14, 2018
Biotech Showcase Video Interview with Jeff Jonker, President of NGM Portfolio News / By admin February 5, 2018
